Apogee Therapeutics, INC Form 4 insider transactions

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., sold 5,500 shares of common stock on August 5, 2026 for $134.17 per share.

Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., reported a transaction in 15,000 shares of common stock on July 24, 2026.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., reported a transaction in 8,000 shares of common stock on July 14, 2026.

Michael Henderson, CEO of Apogee Therapeutics, sold 20,000 shares of common stock for $133.63 per share under a Rule 10b5-1 trading plan, and also gifted 75,046 shares to a donor-advised fund.

Carl Dambkowski, Chief Medical Officer at Apogee Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock, including trades executed under a Rule 10b5-1 plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., reported the sale of 26,400 shares of common stock executed under a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson reported the sale of 80,000 shares under a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold 19,000 shares of common stock on June 10, 2026, under a pre-arranged 10b5-1 trading plan.

Director Tomas Kiselak of Fairmount Funds Management was granted an option to purchase 7,657 shares of Apogee Therapeutics common stock.

Director Nimish P. Shah was granted options to purchase 7,657 shares of Apogee Therapeutics common stock.

Director Mark McKenna was granted 7,657 stock options in Apogee Therapeutics, Inc. as part of a standard equity compensation arrangement.

Apogee Therapeutics director William A. Jones Jr. was granted 7,657 stock options as part of his compensation package.

Director Jennifer A. Fox was granted 7,657 stock options in Apogee Therapeutics, Inc. as disclosed in a recent SEC Form 4 filing.

Director Lisa Bollinger was granted 7,657 stock options in Apogee Therapeutics, Inc. as part of standard equity compensation.

Chief Medical Officer Carl Dambkowski exercised options and sold shares of Apogee Therapeutics under a 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Chief Medical Officer Carl Dambkowski exercised options and sold 5,500 shares of Apogee Therapeutics common stock.

Apogee Therapeutics CFO Jane Henderson sold 2,000 shares of common stock on May 1, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson exercised 3,000 stock options at a price of $22.86 per share.

Apogee Therapeutics CFO Jane Henderson sold 2,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson reported the sale of 20,000 shares of common stock under a pre-arranged trading plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., reported transactions involving the acquisition and disposition of company common stock on April 1, 2026, executed under a Rule 10b5-1 trading plan.

Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., reported the sale of 2,000 shares of common stock on April 1, 2026, executed under a Rule 10b5-1 trading plan.

Apogee Therapeutics CFO Jane Henderson sold 2,000 shares of common stock at $85 per share under a pre-arranged trading plan.

Apogee Therapeutics CEO Michael Henderson reported the sale of 19,000 shares of common stock for approximately $1.5 million, executed under a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 2,000 shares of common stock on March 2, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of common stock for approximately $1.27 million through a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Apogee Therapeutics' Chief Financial Officer, Jane Henderson, sold 2,000 shares of common stock on February 2, 2026, under a Rule 10b5-1 trading plan.